Sort
15,842 grants matching “pancreatic cancer”
Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity
$349,385David C Linehan · University Of Rochester · R01 · FY2019 · CA
INTEGRATED MICROFLUIDIC MAGNETIC CTC SORTER AND ENUMERATOR FOR EARLY DIAGNOSIS AND MANAGEMENT OF PANCREATIC CANCER
$349,382Regents Of The University Of Michigan · · FY2013 · Department of Defense
Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial chemotherapy of pancreatic ductal adenocarcinoma
$349,329Juan Luis Vivero-Escoto · University Of North Carolina Charlotte · R01 · FY2022 · CA
Novel Strategies to Potentiate a Ras-targeted Oncolytic Herpes Simplex Virus
$349,308Xiaoliu Zhang · University Of Houston · R01 · FY2016 · CA
Core D: Digital Pathology and CyTOF
$349,207Robert A Anders · Johns Hopkins University · P01 · FY2021 · CA
Core D: Digital Pathology and CyTOF
$349,207Robert A Anders · Johns Hopkins University · P01 · FY2025 · CA
Normalizing PDAC stroma with PCBP2 siRNA nanoparticles to improve the antitumor activity of chemotherapy and immunotherapy
$349,193Kun Cheng · University Of Missouri Kansas City · R01 · FY2024 · CA
Preclinical development of a novel antibody conjugate for intraoperative detection of pancreatic cancer
$349,192Aaron M. Mohs · University Of Nebraska Medical Center · R01 · FY2023 · CA
Regulation of Growth Factor Activity by A2 Macroglobulin
$349,179University Of Virginia Charlottesville · R01 · FY2002 · CA
Defining the role of macropinocytosis in solid tumor growth and therapeutic resistance
$348,993Aimee L Edinger · University Of California-Irvine · R01 · FY2020 · CA
Tailoring Therapy to Pancreatic Cancer Subtypes
$348,958Eric Collisson · University Of California, San Francisco · R01 · FY2021 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2020 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2016 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2021 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2018 · CA
Prevention of solar UV-induced skin cancer by targeting LTA4H
$348,844Zigang Dong · University Of Minnesota · R01 · FY2018 · CA
Mechanisms Underlying Replication Stress And Genome Instability Upon BRCA2 Deficiency
$348,844Shailja Pathania · University Of Massachusetts Boston · R01 · FY2022 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2022 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2017 · CA
Prevention of solar UV-induced skin cancer by targeting LTA4H
$348,844Zigang Dong · University Of Minnesota · R01 · FY2017 · CA
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY
$348,844David G Denardo · Washington University · R01 · FY2018 · CA
IRAK4 As a Novel Immunotherapeutic Target in Pancreatic Ductal Adenocarcinoma
$348,844Kian H Lim · Washington University · R37 · FY2020 · CA
Systemic Therapy with Infectivity-Selective Oncolytic Adenovirus for PDAC
$348,844Masato Yamamoto · University Of Minnesota · R01 · FY2017 · CA
Pharmacological Ascorbate as a Radiosensitizer in Pancreatic Cancer
$348,844Joseph J Cullen · University Of Iowa · R01 · FY2018 · CA
Prevention of solar UV-induced skin cancer by targeting LTA4H
$348,844Zigang Dong · University Of Minnesota · R01 · FY2015 · CA